Targeting inflammatory pathways in axial spondyloarthritis

por Furst, Daniel E., Louie, James S.
Publicado 2019

Safety and feasibility of umbilical cord mesenchymal stem cells in treatment-refractory systemic lupus erythematosus nephritis: time for a double-blind placebo-controlled trial to...

por Woodworth, Thasia G, Furst, Daniel E
Publicado 2014

Description of the Efficacy and Safety of Three New Biologics in the Treatment of Rheumatoid Arthritis

por Storage, Steven S., Agrawal, Harsh, Furst, Daniel E.
Publicado 2010

The impact of tocilizumab on physical function and quality of life in patients with rheumatoid arthritis: a systematic literature review and interpretation

por Townes, Shatara V, Furst, Daniel E, Thenkondar, Anuradha
Publicado 2012

Biosimilars and the extrapolation of indications for inflammatory conditions

por Tesser, John RP, Furst, Daniel E, Jacobs, Ira
Publicado 2017

Review: Hematopoietic Stem Cell Transplantation for Scleroderma: Effective Immunomodulatory Therapy for Patients With Pulmonary Involvement

por Sullivan, Keith M., Shah, Ankoor, Sarantopoulos, Stefanie, Furst, Daniel E.
Publicado 2016

Clinical trials in systemic sclerosis: lessons learned and outcomes

por Matucci-Cerinic, Marco, Steen, Virginia D, Furst, Daniel E, Seibold, James R
Publicado 2007

Review of Routine Laboratory Monitoring for Patients with Rheumatoid Arthritis Receiving Biologic or Nonbiologic DMARDs

por Rigby, William F. C., Lampl, Kathy, Low, Jason M., Furst, Daniel E.
Publicado 2017

Examination of the Validity of Skin Ultrasound to Quantitate Skin Involvement for Multicenter Clinical Trials in Patients with Systemic Sclerosis (SSc): A Systematic Literature Rev...

por Aly, Omar M., Kafaja, Kevin L., Suliman, Yossra A., Furst, Daniel E.
Publicado 2021

An International, Web-Based, Prospective Cohort Study to Determine Whether the Use of ACE Inhibitors prior to the Onset of Scleroderma Renal Crisis Is Associated with Worse Outcome...

por Hudson, Marie, Baron, Murray, Lo, Ernest, Weinfeld, Joanna, Furst, Daniel E., Khanna, Dinesh
Publicado 2010

Longer durations of antitumour necrosis factor treatment are associated with reduced risk of cardiovascular events in patients with rheumatoid arthritis

por Nurmohamed, Michael, Bao, Yanjun, Signorovitch, James, Trahey, Alex, Mulani, Parvez, Furst, Daniel E
Publicado 2015

Considering Immuno-autonomics in Stratifying Successful Treatment of Rheumatoid Arthritis with Tumor Necrosis Factor Inhibition: Comment on Cohen et al. Rheumatol Ther 2021 June 19

por Holman, Andrew J., Keystone, Edward, Choy, Ernest, Furst, Daniel, Taylor, Peter, Gaylis, Norman
Publicado 2021

GMP-Compliant Isolation and Large-Scale Expansion of Bone Marrow-Derived MSC

por Fekete, Natalie, Rojewski, Markus T., Fürst, Daniel, Kreja, Ludwika, Ignatius, Anita, Dausend, Julia, Schrezenmeier, Hubert
Publicado 2012

Wide-field imaging of birefringent synovial fluid crystals using lens-free polarized microscopy for gout diagnosis

por Zhang, Yibo, Lee, Seung Yoon Celine, Zhang, Yun, Furst, Daniel, Fitzgerald, John, Ozcan, Aydogan
Publicado 2016

Risk of Malignancies in Patients with Rheumatoid Arthritis Treated with Rituximab: Analyses of Global Postmarketing Safety Data and Long-Term Clinical Trial Data

por Emery, Paul, Furst, Daniel E., Kirchner, Petra, Melega, Simone, Lacey, Stuart, Lehane, Patricia B.
Publicado 2019

Repository Corticotropin Injection for Active Rheumatoid Arthritis Despite Aggressive Treatment: A Randomized Controlled Withdrawal Trial

por Fleischmann, Roy, Furst, Daniel E., Connolly-Strong, Erin, Liu, Jingyu, Zhu, Julie, Brasington, Richard
Publicado 2020

Misalignment between physicians and patient satisfaction with psoriatic arthritis disease control

por Furst, Daniel E., Tran, Melody, Sullivan, Emma, Pike, James, Piercy, James, Herrera, Vivian, Palmer, Jacqueline B.
Publicado 2017

Biologic and Targeted Synthetic DMARD Utilization in the United States: Adelphi Real World Disease Specific Programme for Rheumatoid Arthritis

por Holdsworth, Elizabeth A., Donaghy, Bethany, Fox, Kathleen M., Desai, Pooja, Collier, David H., Furst, Daniel E.
Publicado 2021

Agreements and Discrepancies between FDA Reports and Journal Papers on Biologic Agents Approved for Rheumatoid Arthritis: A Meta-Research Project

por Amarilyo, Gil, Furst, Daniel E., Woo, Jennifer M. P., Li, Wen, Bliddal, Henning, Christensen, Robin, Tarp, Simon
Publicado 2016

Patient‐Reported Outcomes From a Two‐Year Head‐to‐Head Comparison of Subcutaneous Abatacept and Adalimumab for Rheumatoid Arthritis

por Fleischmann, Roy, Weinblatt, Michael E., Schiff, Michael, Khanna, Dinesh, Maldonado, Michael A., Nadkarni, Anagha, Furst, Daniel E.
Publicado 2016